Clinical Trial Update: Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating safety, tolerability, and renal effects of APX-115 in subjects with type 2 diabetes and nephropathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• APX-115

Snippet

Sponsor: Aptabio Therapeutics, Inc. | Conditions: Diabetic Nephropathies, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED